Aytu BioPharma Inc (AYTU)
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-11-05
$1.81-5.73%
Close 2026-11-05 · 1-day change
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-11-05
QuarterlyIQ Insights · AYTU
Next print, the company's guidance track record, and the earnings events we've seen in the last few years.
Likelihood the company beats analyst consensus on its next print. Read from its own beat history plus how sector peers have been reporting. Not a price-direction call: a serial beater often has the beat already priced in.
Prints it beat consensus, recent quarters.
Indicative, not a guarantee. Base rate ~71%.
Industry peers that beat since this name last reported.
Management's most recent EPS guidance action.
expected = 0.35*own_median(25.0) + peer(0.2*6.9) + term(0.0) → 10.13% (capped ±15.0)
in 6 days
Average absolute move on past earnings days.
Annualized: recent baseline volatility.
Of the last 0 guided quarters.
Actual vs. guided EPS, signed.
Excess return vs. sector ETF, day after print.
Earnings prints and pre-announcements detected in the SEC filing stream.
Results of Operations and Financial Condition. On September 22, 2026, Aytu BioPharma, Inc. (the “Company”) issued a press release announcing its fiscal 2026 fourth quarter operational and financial results. As indicated in the press release, the Company scheduled a conference call and live audio webcast for September 22, 2026, at 4:30 p.m. Eastern time to discuss the operational and financial results and to answer questions. The conference call is publicly accessible via webcast and telephone…
Quarterly EPS and revenue actuals vs. consensus across the last eight quarters (including beat/miss size and the forward consensus heading into the next print) are on the way.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Results of Operations and Financial Condition. On May 13, 2026, Aytu BioPharma, Inc. (the “Company”) issued a press release announcing its fiscal 2026 third quarter operational and financial results. As indicated in the press release, the Company scheduled a conference call and live audio webcast for May 13, 2026, at 4:30 p.m. Eastern time to discuss the operational and financial results and to answer questions. The conference call is publicly accessible via webcast and telephone (available l…
Results of Operations and Financial Condition. See the disclosures in
Results of Operations and Financial Condition. On February 3, 2026, Aytu BioPharma, Inc. (the “Company”) issued a press release announcing its fiscal 2026 second quarter operational and financial results. As indicated in the press release, the Company scheduled a conference call and live audio webcast for February 3, 2026, at 4:30 p.m. Eastern time to discuss the operational and financial results and to answer questions. The conference call is publicly accessible via webcast and telephone (av…
Results of Operations and Financial Condition. On November 13, 2025, Aytu BioPharma, Inc. (the “Company”) issued a press release announcing its fiscal 2026 first quarter operational and financial results. As indicated in the press release, the Company scheduled a conference call and live audio webcast for November 13, 2025, at 4:30 p.m. Eastern time to discuss the operational and financial results and to answer questions. The conference call is publicly accessible via webcast and telephone (a…
Results of Operations and Financial Condition. On September 23, 2025, Aytu BioPharma, Inc. (the “Company”) issued a press release announcing its fiscal 2025 full year and fourth quarter operational and financial results. As indicated in the press release, the Company scheduled a conference call and live audio webcast for September 23, 2025, at 4:30 p.m. Eastern time to discuss the operational and financial results and to answer questions. The conference call is publicly accessible via webcast…
Results of Operations and Financial Condition. On May 14, 2025, Aytu BioPharma, Inc. (the “Company” or “Aytu”) issued a press release announcing its fiscal 2025 third quarter operational and financial results. As indicated in the press release, the Company scheduled a conference call and live audio webcast for May 14, 2025, at 4:30 p.m. Eastern time to discuss the operational and financial results and to answer questions. The conference call is publicly accessible via webcast and telephone (a…
Results of Operations and Financial Condition. On February 12, 2025, Aytu BioPharma, Inc. (the “Company” or “Aytu”) issued a press release announcing its fiscal 2025 second quarter operational and financial results. As indicated in the press release, the Company scheduled a conference call and live audio webcast for February 12, 2025, at 4:30 p.m. Eastern time to discuss the operational and financial results and to answer questions. The conference call is publicly accessible via webcast and t…
Results of Operations and Financial Condition. On November 13, 2024, Aytu BioPharma, Inc. (the “ Company ” or “ Aytu ”) issued a press release announcing its fiscal 2025 first quarter operational and financial results. As indicated in the press release, the Company scheduled a conference call and live audio webcast for November 13, 2024, at 4:30 p.m. Eastern time to discuss the operational and financial results and to answer questions. The conference call is publicly accessible via webcast an…
Results of Operations and Financial Condition. On September 26, 2024, Aytu BioPharma, Inc. (the “Company”) issued a press release announcing its fiscal 2024 full year and fourth quarter operational and financial results. As indicated in the press release, the Company scheduled a conference call and live audio webcast for September 26, 2024, at 4:30 p.m. Eastern time to discuss the operational and financial results and to answer questions. The conference call is publicly accessible via webcast…
Results of Operations and Financial Condition. On May 15, 2024, Aytu BioPharma, Inc. (the “Company”) issued a press release announcing its operational and financial results for the fiscal quarter ended March 31, 2024. As indicated in the press release, the Company scheduled a conference call and live audio webcast for May 15, 2024, at 4:30 p.m. Eastern time to discuss the operational and financial results and to answer questions. The conference call is publicly accessible via webcast and tele…
Results of Operations and Financial Condition. On February 14, 2024, Aytu BioPharma, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended December 31, 2023. As indicated in the press release, the Company scheduled a conference call and live audio webcast for February 14, 2024, at 4:30 p.m. Eastern time to discuss the operational and financial results and to answer questions. The conference call is publicly accessible via webcast and telepho…
Results of Operations and Financial Condition. On November 14, 2023, the Company issued a press release announcing the Company’s financial results for the fiscal quarter ended September 30, 2023. A copy of the press release is furnished herewith as Exhibit 99.1. In accordance with General Instruction B.2 of Form 8-K, the information in the press release attached as Exhibit 99.1 hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as a…
Results of Operations and Financial Condition. On October 26, 2023, Aytu BioPharma, Inc (the “Company”) issued a press release announcing the Company’s approval of the Cotempla XR-ODT® manufacturing site transfer prior approval supplement . A copy of the press release is furnished herewith as Exhibit 99.1. In accordance with General Instruction B.2 of Form 8-K, the information in the press release attached as Exhibit 99.1 hereto shall not be deemed to be “filed” for purposes of Section 18 of…
Results of Operations and Financial Condition. On September 27, 2023, the Company issued a press release announcing the Company’s financial results for the fiscal quarter and year ended June 30, 2023. A copy of the press release is furnished herewith as Exhibit 99.1. In accordance with General Instruction B.2 of Form 8-K, the information in the press release attached as Exhibit 99.1 hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934,…
Results of Operations and Financial Condition. On May 11, 2023, the Company issued a press release announcing the Company’s financial results for the fiscal quarter ended March 31, 2023. A copy of the press release is furnished herewith as Exhibit 99.1. In accordance with General Instruction B.2 of Form 8-K, the information in the press release attached as Exhibit 99.1 hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (t…